KDR and metastatic prostate carcinoma: Using orthotopic and metastatic prostate cancer mouse models, inhibition of the VEGF/VEGFR axis by an antibody (DC101) against the VEGF receptor, flk-1, reduced tumor-induced angiogenesis and suppressed metastasis, and this was associated with diminished MMP9 production by endothelial cells [159].